You are in: eMedicine Specialties > Emergency Medicine > OPHTHALMOLOGY Corneal AbrasionArticle Last Updated: Jul 27, 2007AUTHOR AND EDITOR INFORMATIONAuthor: Robert M Howell, MD, FACEP, Associate Clinical Professor, Department of Family Medicine, Creighton University School of Medicine; Consulting Staff, Department of Emergency Medicine, Creighton University Medical Center/Saint Joseph Hospital Robert M Howell is a member of the following medical societies: American College of Emergency Physicians Editors: Debra Slapper, MD, Consulting Staff, Department of Emergency Medicine, St Anthony's Hospital; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Douglas Lavenburg, MD, Clinical Professor, Department of Emergency Medicine, Christiana Care Health Systems; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Barry E Brenner, MD, PhD, FACEP, Program Director, Department of Emergency Medicine, University Hospitals, Case Medical Center Author and Editor Disclosure Synonyms and related keywords: corneal abrasion, scratched cornea, scraped eye, scraped cornea, eye trauma, scratched eye, corneal surface INTRODUCTIONBackgroundCorneal abrasion is a scraping away or denuding of the corneal surface resulting from external forces physically applied to the corneal surface. PathophysiologyThe cornea of the eye and, commonly, the bulbar conjunctiva, are affected. Minor or superficial abrasions involve only the corneal epithelium. Severe injuries also involve the deeper, thicker stromal layer. FrequencyUnited StatesCorneal abrasions are a common ophthalmologic cause of ED visits. Mortality/MorbidityDeath is uncommon. Significant morbidity is uncommon but is mostly observed in conjunction with infectious complications or allergies to medications used in treatment. Recurrent erosions are a common complication of abrasions, particularly in patients with epithelial basement membrane dystrophy. AgeIncidence of corneal abrasion is more common in younger, active individuals. Occurrence is unusual in elderly adults. CLINICALHistory
Physical
Causes
DIFFERENTIALSConjunctivitis Corneal Laceration Corneal Ulceration and Ulcerative Keratitis Glaucoma, Acute Angle-Closure Iritis and Uveitis
|
| Drug Name | Trimethoprim/polymyxin B (Polytrim) |
|---|---|
| Description | Used for treatment of ocular infections involving cornea or conjunctiva. Available as solution and ointment. |
| Adult Dose | Solution: 1-2 gtt q2h in the affected eye while awake Ointment: Apply 0.5-inch ribbon into conjunctival sac qid |
| Pediatric Dose | <2 months: Not established >2 months: Administer as in adults |
| Contraindications | Documented hypersensitivity; viral and mycobacterial infections of the eye; fungal diseases |
| Interactions | None reported |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Do not use in deep ocular infections or in those likely to become systemic; prolonged use of antibiotics or repeated therapy may result in bacterial or fungal overgrowth of nonsusceptible organism |
| Drug Name | Sulfacetamide sodium 10% (Sulamyd, Bleph-10) |
|---|---|
| Description | Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA. Available as solution, ointment, and lotion. |
| Adult Dose | Solution: 1-3 gtt q2-3h in the affected eye, while awake; less frequently at night Ointment: Apply 0.5-inch ribbon 1-4 times/d into conjunctival sac |
| Pediatric Dose | <2 months: Not established >2 months: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Effects decreased when used concurrently with gentamicin |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in severely dried eye; ointment may retard corneal epithelial healing |
| Drug Name | Tobramycin (Tobrex) |
|---|---|
| Description | Aminoglycoside that interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, causing a defective bacterial cell membrane. Available as solution, ointment, and lotion. |
| Adult Dose | Solution: 1-2 gtt q4h in the affected eye, while awake; less frequently at night Severe infections: 2 gtt q30-60min for the first 24 h, followed by less frequent intervals Ointment: Apply 0.5-inch ribbon bid/tid into conjunctival sac Severe infections: Apply q3-4h |
| Pediatric Dose | <2 years: Not established >2 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use in deep-seated ocular infections or in those that may become systemic; prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organisms |
| Drug Name | Norfloxacin (Chibroxin) |
|---|---|
| Description | Inhibits bacterial growth by inhibiting DNA gyrase. |
| Adult Dose | 1-2 gtt qid for 7 d Suspected corneal ulcers: 1-2 gtt qh for first 24 h then qid for 7 d |
| Pediatric Dose | <1 year: Not established >1 year: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use in deep ocular infections likely to become systemic; prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organisms |
| Drug Name | Ciprofloxacin (Ciloxan) |
|---|---|
| Description | Inhibits bacterial growth by inhibiting DNA gyrase. |
| Adult Dose | 1-2 gtt qid for 7 d Suspected corneal ulcers: 1-2 gtt qh for first 24 h then qid for 7 d |
| Pediatric Dose | <1 year: Not established >1 year: Administer as in adults |
| Contraindications | Documented hypersensitivity; viral, mycobacterial, and fungal eye infections; avoid coadministration with steroid combinations after uncomplicated removal of a foreign body from cornea |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use in deep ocular infections likely to become systemic; prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organisms |
| Drug Name | Gentamicin (Genoptic) |
|---|---|
| Description | Aminoglycoside antibiotic used for gram-negative bacterial coverage. |
| Adult Dose | Solution: 1-2 gtt q4h in the affected eye, while awake; less frequently at night Severe infections: 2 gtt q30-60min for the first 24 h, followed by less frequent intervals |
| Pediatric Dose | <2 years: Not established >2 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; mycobacterial, viral, and fungal infections of the eye; patients taking steroid combinations after uncomplicated removal of a foreign body from cornea |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Do not use to treat ocular infections that may become systemic; prolonged or repeated antibiotic therapy may result in bacterial or fungal overgrowth of nonsusceptible organisms and may lead to a secondary infection |
These agents are used for analgesia to facilitate an adequate examination. These agents should never be prescribed for home use because they may cause a secondary keratitis, compromise epithelial wound healing, and block effective corneal protective reflexes and sensation.
| Drug Name | Proparacaine 0.5% (Ophthaine) |
|---|---|
| Description | Least irritating of all topical anesthetics. Prevents initiation and transmission of impulse at the nerve cell membrane by stabilizing it and decreasing ion permeability. Onset of action for this anesthetic takes place within 20 sec of application. Anesthetic effect may last up to 10-15 min. |
| Adult Dose | 1-2 gtt of 0.5% solution in the eye q5-10min for 5-7 doses |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; prolonged use |
| Interactions | Increases effects of phenylephrine and tropicamide |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in cardiac disease or hyperthyroidism and those with abnormal or reduced levels of plasma esterases |
| Drug Name | Tetracaine HCl 0.5% (Pontocaine) |
|---|---|
| Description | Local anesthetic that blocks both initiation and conduction of nerve impulses by decreasing neuronal membrane's permeability to sodium ions. Results are inhibition of depolarization, blocking conduction of impulse. Available in solution and ointment. Onset of action takes place within 1 min of application and anesthetic effect may last up to 15-20 min. This medication stings considerably on application. |
| Adult Dose | Solution: 1-2 gtt Ointment: Apply 0.5-inch ribbon into conjunctival fornix |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Antagonizes effect of sulfonamides and aminosalicylic acid |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in cardiac disease and hyperthyroidism; use may delay wound healing |
Some ophthalmologists are advocating that diclofenac (Voltaren) or ketorolac (Acular) drops and a disposable soft contact lens be used in addition to antibiotic drops. This therapy may prove to be an effective alternative to patching, permitting the patient to maintain binocular vision during treatment. Compared with patching, the contact lens used with the NSAID may reduce pain.
Weaver et al found 3 recent good to strong studies that showed NSAIDs, when used alone, are effective at diminishing pain in patients with corneal abrasions who are required to return to immediate work, particularly where potential medication-induced sedation is contraindicated.3
| Drug Name | Diclofenac (Voltaren) |
|---|---|
| Description | Inhibits prostaglandin synthesis by decreasing the activity of the enzyme cyclooxygenase, which results in decreased formation of prostaglandin precursors. |
| Adult Dose | 1 gtt into affected eye qid, continue for a maximum of 2 wk |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Corneal thinning may occur |
| Drug Name | Ketorolac tromethamine 0.5% (Acular) |
|---|---|
| Description | Inhibits prostaglandin synthesis by decreasing activity of the enzyme, cyclooxygenase, which results in decreased formation of prostaglandin precursors, which, in turn, results in reduced inflammation. |
| Adult Dose | 1 gtt into affected eye qid, continue for a maximum of 2 wk |
| Pediatric Dose | <12 years: Not established >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Perform ophthalmologic studies in patients who develop eye complaints during therapy; discontinue therapy if changes are noted; changes may include blurred or diminished vision, corneal deposits and retinal disturbances, scotomata, changes in color vision, and macula degeneration |
All but the most minor abrasions usually require a strong oral narcotic analgesic.
| Drug Name | Hydrocodone bitartrate and acetaminophen (Vicodin ES) |
|---|---|
| Description | Drug combination indicated for the relief of moderate to severe pain. |
| Adult Dose | 1-2 tab or cap PO q4-6h prn |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose PO acetaminophen q4-6h prn; not to exceed 2.6 g/d acetaminophen or 5 mg of hydrocodone bitartrate/dose >12 years: 750 mg PO acetaminophen q4h; not to exceed 5 doses/d acetaminophen or 10 mg of hydrocodone bitartrate/dose |
| Contraindications | Documented hypersensitivity |
| Interactions | Coadministration with phenothiazines may decrease analgesic effects; toxicity increases with CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Tabs contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates because this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Oxycodone and acetaminophen (Percocet, Roxicet, Roxilox, Tylox) |
|---|---|
| Description | Drug combination indicated for the relief of moderate to severe pain. |
| Adult Dose | 1-2 tab or cap PO q4-6h or prn |
| Pediatric Dose | Based on oxycodone dose: 0.05-0.15 mg/kg/dose PO q4-6h or prn; not to exceed 5 mg/dose of oxycodone |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenothiazines may decrease analgesic effects; toxicity increases with coadministration of either CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Duration of action may increase in elderly persons; be aware of total daily dose of acetaminophen patient is receiving; do not exceed 4000 mg/d of acetaminophen; higher doses may cause liver toxicity |
No good evidence exists in the literature to support the common practice of using cycloplegics/mydriatics for the treatment of routine corneal abrasions. However, most ophthalmologists believe that the instillation of a long-acting cycloplegic agent can provide significant relief in patients who have extensive corneal abrasions, a large degree of photophobia, and blepharospasm. These agents relax any ciliary muscle spasm that may cause a deep, aching pain and photophobia.
Cycloplegic agents are mydriatics; thus, to prevent an acute angle-closure attack, ensure that the patient does not have narrow-angle glaucoma.
| Drug Name | Homatropine 2%, 5% (Isopto Homatropine) |
|---|---|
| Description | Blocks the response of the iris sphincter muscle and the accommodative muscle of ciliary body to cholinergic stimulation. This results in dilation and loss of accommodation. Useful for patients with dark iris. Induces mydriasis in 10-30 min and cycloplegia in 30-90 min. These effects last up to 48 h. |
| Adult Dose | Instill 1-2 gtt of 2% solution or 1 gtt of 5% solution to induce cycloplegia; repeat in 15-20 min prn For prolonged cycloplegia: 1-2 gtt up to q3-4h; if heavily pigmented irides, larger doses may be necessary |
| Pediatric Dose | Apply 1 gtt of 2% solution immediately before the procedure; repeat at 10-min intervals prn |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Exercise caution in patients who may have increased IOP (eg, elderly persons); toxic anticholinergic systemic adverse effects can occur, but are rare when used sparingly; adverse effects are more common in children, especially infants; compressing lacrimal sac by digital pressure for 1-3 min following instillation minimizes systemic absorption |
| Drug Name | Cyclopentolate HCl 1% (Cyclogyl) |
|---|---|
| Description | DOC in the treatment of cornea abrasions. Prevents the muscle of the ciliary body and the sphincter muscle of the iris from responding to cholinergic stimulation, causing mydriasis and cycloplegia. Induces mydriasis in 30-60 min and cycloplegia in 25-75 min. These effects last up to 24 h. |
| Adult Dose | 1 gtt of 1% solution is usually adequate to induce cycloplegia; repeat in 5-10 min prn |
| Pediatric Dose | Infants: Before examination, instill 1 gtt of 0.5% into each eye q5-10min >1 year: Instill 1 gtt of a 0.5%, 1%, or 2% solution to induce cycloplegia; repeat in 5-10 min prn |
| Contraindications | Documented hypersensitivity; narrow-angle glaucoma; albinotic patients |
| Interactions | Decreases effects of carbachol and cholinesterase inhibitors |
| Pregnancy | |
| Precautions | Exercise caution in patients who may have increased IOP (eg, elderly persons); can cause toxic anticholinergic systemic adverse effects (common in children, especially infants) but incidence rare when used sparingly; compressing lacrimal sac by digital pressure for 1-3 min following application may minimize systemic absorption |
Article Last Updated: Jul 27, 2007